This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression

Kathleen S. Bingham, MD; Anthony J. Rothschild, MD; Benoit H. Mulsant, MD; Ellen M. Whyte, MD; Barnett S. Meyers, MD; Samprit Banerjee, PhD; Katalin Szanto, MD; and Alastair J. Flint, MB; on behalf of the STOP-PD Study Group

Published: April 25, 2017

Article Abstract

Objective: To examine the association between baseline suicidality and outcome of major depression in a randomized controlled trial of the pharmacotherapy of psychotic depression and to explore the interaction of suicidality, randomized treatment assignment, and depression outcome.

Methods: This study was a secondary analysis of data from 258 persons aged 18 years or older with DSM-IV-defined major depressive disorder with psychotic features who participated in a 12-week randomized controlled trial (RCT) comparing olanzapine plus sertraline with olanzapine plus placebo (the Study of the Pharmacotherapy of Psychotic Depression [STOP-PD], which ran from 2002 to 2007). The independent variable was baseline suicidality, defined by 4 groups (suicide attempt in the current episode, active suicidal ideation, passive suicidal ideation, and no suicidality). The outcome variables were change in 16-item Hamilton Depression Rating Scale (HDRS16) total score (excluding the suicide item) over time and remission of psychotic depression over time.

Results: Suicidality groups did not significantly differ on baseline HDRS16 total score. Baseline suicidality group was significantly associated with change in HDRS16 score over time in the sample as a whole (F3,1394 = 8.17; P < .0001), but was not significantly associated with probability of remission over time. Among participants assigned to olanzapine and placebo, persons with no suicidality had a significantly greater reduction in HDRS16 total score compared to those with passive suicidal ideation (7.5-point difference in change scores between the 2 groups; 95% CI, 4.3-10.7 t1394 = 4.61, P < .0001), active suicidal ideation (4.4 points; 95% CI, 1.4-7.4; t1394 = 2.85, P = .0176), or suicide attempts (6.1 points; 95% CI, 2.8-9.4; t1394 = 3.66, P = .0015). The 12-week change from baseline in HDRS16 score for patients with no suicidality was not significantly different between the 2 treatment arms. However, the 12-week HDRS16 improvement was significantly greater in the olanzapine plus sertraline arm, compared with the olanzapine plus placebo arm, for patients with suicide attempts (8.7-point difference in change scores between the 2 groups; 95% CI, 5.1-12.4; t1394 = 4.75, P < .0001), active suicidal ideation (8.1 points; 95% CI, 4.5-11.7; t1394 = 4.38, P < .0001), or passive suicidal ideation (5.7 points; 95% CI, 2.2-9.2; t1394 = 3.23, P = .0012), respectively.

Conclusions: Baseline suicidality predicted worse acute treatment outcome of psychotic depression. However, participants with suicidality had a better outcome when treated with the combination of olanzapine and sertraline than when treated with olanzapine plus placebo.

Trial Registration: identifier: NCT00056472‘ ‹

Volume: 78

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF